Simulations Plus Q3 revenue $16.2M (+9%), EPS $0.20; maintains FY guidance; completes Immunetrics acquisition

Simulations Plus, Inc.

2023-Q3 EPS reported $0.46 revenue$43,948,000

Q3 revenue $16.2M (+9% YoY); diluted EPS $0.20 (flat); adjusted EBITDA $6.5M (40% margin).
Software revenue $10.6M (+10%), services $5.6M (+5%); gross margin 82%.
Nine-month revenue $43.9M (+4%); net income $9.4M ($0.46 EPS) vs $11.5M ($0.56) prior year.
Completed $20M ASR program: 492,041 shares repurchased at $40.65 avg; dividend of $0.06/share declared.
Acquired Immunetrics for $15.5M cash + up to $8M earn-out, closed June 16; expands QSP into oncology/immunology.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Simulations Plus, Inc. reported Third quarter of fiscal 2023 ended May 31, 2023 results: revenue $16.2 million, net income $4.0 million, EPS $0.20. Guidance reaffirmed.

Period: Third quarter of fiscal 2023 ended May 31, 2023
Revenue: $16.2 million
Net income: $4.0 million
EPS: $0.20
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Simulations Plus, Inc. filing history →

Source: SEC EDGAR

accession 0001023459-23-000085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.